The Relative Strength (RS) Rating for Vertex Pharmaceuticals entered a higher percentile Wednesday, as it got a lift from 61 to 76.
This proprietary rating measures technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History reveals that the best-performing stocks tend to have an RS Rating north of 80 in the early stages of their moves. See if Vertex Pharmaceuticals can continue to show renewed price strength and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Vertex Pharmaceuticals is building a flat base with a 510.63 entry. See if it can break out in heavy trading.
Top and bottom line growth moved higher last quarter. Earnings were up 7%, compared to 2% in the prior report. Revenue increased from 6% to 12%.
Vertex Pharmaceuticals earns the No. 13 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
